Treatment library
Loading treatment roster
Preparing current medications, procedures, devices, and historical context.
Treatment library
Preparing current medications, procedures, devices, and historical context.
Novo Nordisk’s branded liraglutide product for chronic weight management. It predates the weekly semaglutide and tirzepatide era and remains part of the obesity-medication landscape.
FDA-approved for chronic weight management in eligible adults and adolescents 12 and older.
GLP-1 receptor agonist
Coverage is inconsistent and has often become less favorable as plans reassess obesity benefits and newer brands enter the market.
GLP-1 receptor agonist
Novo Nordisk’s branded liraglutide product for chronic weight management. It predates the weekly semaglutide and tirzepatide era and remains part of the obesity-medication landscape.
medication
current
2014
Saxenda
liraglutide
Novo Nordisk
No generic equivalent for Saxenda in the U.S. obesity indication.
liraglutide
Branded medication with meaningful cash-pay cost. Daily injection and older efficacy profile can affect value perception versus newer weekly drugs.
Coverage is inconsistent and has often become less favorable as plans reassess obesity benefits and newer brands enter the market.
FDA-approved for adults with BMI of 30 or higher, or BMI of 27 or higher with at least one weight-related comorbidity such as hypertension, dyslipidemia, or type 2 diabetes, when diet and exercise alone have not been enough. Also approved for adolescents 12 and older with obesity.
Adults with BMI of 30 or higher (obesity), or BMI of 27 or higher (overweight) with at least one weight-related comorbidity. Also approved for adolescents 12 and older with obesity.
The daily injection is the biggest practical difference from newer options. Average weight loss in trials was roughly 8%, compared with roughly 15% for Wegovy and roughly 20% for Zepbound. Saxenda still gets prescribed when insurance blocks the newer GLP-1s, when supply is short, or when a clinician has a specific reason to prefer liraglutide.
Saxenda was an important early branded obesity GLP-1 and still matters as the pre-Wegovy comparator in older treatment discussions.
Shares core GLP-1 warning themes, including GI intolerance, pancreatitis, gallbladder disease, and boxed warning language about thyroid C-cell tumors in rodents.
nausea, vomiting, diarrhea, constipation, headache
GLP-1 receptor agonist
Once-daily subcutaneous injection with titration from 0.6 mg to a 3 mg maintenance dose.
Prefilled multi-dose injection pen.
These are the official or reference sources used to anchor this treatment profile.
Treatment availability, dosing, cash pricing, and insurance coverage change often. Verify current details with your clinician, pharmacist, surgeon, device program, and insurer before starting, switching, or paying for treatment.